statistiche ricercatore

DONADINI, MARCO PAOLO

Distribuzione geografica

Continente	#
NA - Nord America	5.437
EU - Europa	2.518
AS - Asia	1.427
SA - Sud America	199
AF - Africa	15
OC - Oceania	7
Continente sconosciuto - Info sul continente non disponibili	2
Totale	9.605

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	5.391
IT - Italia	1.298
SG - Singapore	526
UA - Ucraina	371
HK - Hong Kong	233
SE - Svezia	229
TR - Turchia	214
VN - Vietnam	176
CN - Cina	175
BR - Brasile	174
DE - Germania	157
IE - Irlanda	127
GB - Regno Unito	94
RU - Federazione Russa	72
FI - Finlandia	70
IN - India	51
MX - Messico	30
FR - Francia	26
NL - Olanda	16
AT - Austria	14
CA - Canada	13
PL - Polonia	13
AR - Argentina	12
JP - Giappone	10
BD - Bangladesh	9
ES - Italia	9
BE - Belgio	7
ZA - Sudafrica	7
AU - Australia	6
IQ - Iraq	6
EC - Ecuador	5
TW - Taiwan	4
AE - Emirati Arabi Uniti	3
CH - Svizzera	3
CO - Colombia	3
MY - Malesia	3
UZ - Uzbekistan	3
AL - Albania	2
BA - Bosnia-Erzegovina	2
BG - Bulgaria	2
ET - Etiopia	2
EU - Europa	2
IL - Israele	2
JO - Giordania	2
LT - Lituania	2
PT - Portogallo	2
SA - Arabia Saudita	2
VE - Venezuela	2
AM - Armenia	1
BO - Bolivia	1
CI - Costa d'Avorio	1
CL - Cile	1
CR - Costa Rica	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
DZ - Algeria	1
EG - Egitto	1
HR - Croazia	1
ID - Indonesia	1
IR - Iran	1
KE - Kenya	1
KG - Kirghizistan	1
KZ - Kazakistan	1
LB - Libano	1
LK - Sri Lanka	1
MU - Mauritius	1
NG - Nigeria	1
NP - Nepal	1
NZ - Nuova Zelanda	1
PY - Paraguay	1
TT - Trinidad e Tobago	1
Totale	9.605

Salva come PNG Salva come JPEG

Città	#
Milan	890
Fairfield	799
Woodbridge	497
Ashburn	441
Houston	354
Seattle	323
Wilmington	282
Chandler	280
Singapore	278
Ann Arbor	270
Jacksonville	270
Cambridge	240
Hong Kong	233
Izmir	126
Dublin	124
Princeton	123
Dallas	114
Chicago	97
Dearborn	92
The Dalles	88
Nyköping	87
Boardman	83
Los Angeles	82
Dong Ket	70
Rome	67
Beijing	55
San Diego	47
London	33
Ogden	33
New York	31
Salt Lake City	25
Mexico City	23
Ho Chi Minh City	20
Tampa	19
San Mateo	18
Santa Clara	18
Afragola	17
Como	17
Elk Grove Village	14
Varese	14
Helsinki	13
Chennai	11
Denver	11
Nuremberg	11
São Paulo	11
Frankfurt am Main	10
San Francisco	10
Düsseldorf	9
Falkenstein	9
Hefei	9
Tokyo	9
Warsaw	9
Washington	9
Cavaria con Premezzo	8
Columbus	8
Kunming	8
Miami	8
Nanjing	8
Phoenix	8
Ralingen	8
Bangalore	7
Brooklyn	7
Brussels	7
Buffalo	7
Dulles	7
Hanoi	7
Lancaster	7
Munich	7
Olgiate Olona	7
Redmond	7
Sterling	7
Belo Horizonte	6
Campinas	6
Johannesburg	6
Montreal	6
Norwalk	6
Redwood City	6
Verona	6
Council Bluffs	5
Detroit	5
Guangzhou	5
Magnago	5
Manchester	5
Nanchang	5
Orem	5
Stockholm	5
Venezia	5
Amsterdam	4
Berlin	4
Bologna	4
Cagliari	4
Eppelborn	4
Falls Church	4
Fuzhou	4
Gorgonzola	4
Haiphong	4
Kansas City	4
Monza	4
Rio de Janeiro	4
Vienna	4
Totale	7.097

Salva come PNG Salva come JPEG

Nome	#
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: a Delphi analysis of experts	391
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	259
Risk of recurrence of unusual site venous thromboembolism	231
Breadth of complications of long-term oral anticoagulant care	228
Optimal treatment duration of venous thrombosis	220
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients	215
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	210
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	209
Patient selection for thromboprophylaxis in medical inpatients	205
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	195
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	193
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	189
Treating patients with cancer and acute venous thromboembolism	187
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	183
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events	178
Antidotes for the direct oral anticoagulants: What news?	178
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	175
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation	175
Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study).	173
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	172
Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies	171
Pulmonary Embolism in Medical-Surgical Critically Ill Patients	170
An unusual case of cerebral vein thrombosis in a patient with giant cell arteritis	169
Aspirin plus clopidogrel vs aspirin alone for preventing cardiovascular events among patients at high risk for cardiovascular events	164
Brand name versus generic warfarin: a systematic review of the literature.	161
Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging.	159
Age-adjusted D-dimer to rule out deep vein thrombosis: findings from the PALLADIO algorithm	154
Clinical approach to splanchnic vein thrombosis: Risk factors and treatment.	152
Splanchnic vein thrombosis: new risk factors and management	147
Should alcohol be considered a minor protective factor for unprovoked venous thromboembolism?	146
Prognostic clinical prediction rules to identify a low-risk pulmonary embolism: a systematic review and meta-analysis.	143
Antiphospholipid Syndrome: A Challenging Hypercoagulable State with Systemic Manifestations	142
Retrievable vena cava filters: a clinical review.	141
Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors	140
Efficacy and safety of dabigatran etexilate: a narrative review	139
Which patients with unprovoked VTE should receive extended anticoagulation? the minority.	130
Incidence of symptomatic and asymptomatic chronic pulmonary hypertension in patients with a previous episode of pulmonary embolism: a prospective cohort study	126
Combined warfarin-aspirin therapy: what is the evidence for benefit and harm and which patients should (and should not) receive it?	126
Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis	125
Prediction scores do not correlate with clinically adjudicated categories of pulmonary embolism in critically ill patients	119
The short- and long-term risk of venous thromboembolism in patients with acute spinal cord injury: a prospective cohort study.	114
Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET)	113
null	109
Venous thromboembolism: pathophysiology, diagnosis and prophylaxis	109
PROPOSAL FOR THE INCLUSION OF LOW MOLECULAR WEIGHT HEPARINS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED PATIENTS IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES	108
JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis	106
Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience	104
Trattamento del tromboembolismo venoso con anticoagulanti tradizionali e di nuova generazione.	98
Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review	93
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET)	85
Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach	82
Splanchnic vein thrombosis	77
Unusual site thrombosis.	75
Anticoagulant treatment for Upper Extremity Deep Vein thrombosis: a systematic review and meta-analysis	75
Risk of Deep Vein Thrombosis Following a Single Negative Whole-Leg Compression Ultrasound A Systematic Review and Meta-analysis	71
Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation	71
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study.	70
Manuale di emergenze medico-chirurgiche	68
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism	65
Perioperative Management of Patients who are Receiving Oral Anticoagulant Therapy	63
Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study	63
Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis	61
La trombosi venosa profonda e l’embolia polmonare	61
Initial and Long-Term Treatment of Pulmonary Embolism: Current Approach and Future Perspectives	58
Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis	54
Steps towards simplifying the treatment of pulmonary embolism	48
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants	47
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	42
Milvexian and other drugs targeting Factor XI: a new era of anticoagulation?	41
Development of personalized thrombogenesis and thrombin generation assays to assess endothelial dysfunction in cardiovascular diseases	41
Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?	37
Use of artificial intelligence and radiomics for risk stratification in patients with pulmonary embolism: New tools for an old problem	37
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	36
Rates of venous thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital hemophilia A or B: a systematic review	34
Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis	34
DOACs use in extreme body-weighted patients: results from the prospective START-register	30
Geographical and ethnoracial differences in venous thromboembolism and anticoagulation: An expanding horizon	30
Drug–drug interactions between DAAs and anticoagulants or antiplatelets: a position paper of the italian anticoagulation clinics	27
Expert-Based Narrative Review on Compression UltraSonography (CUS) for Diagnosis and Follow-Up of Deep Venous Thrombosis (DVT)	25
The Clinical Impact of the Pulmonary Embolism Severity Index on the Length of Hospital Stay of Patients with Pulmonary Embolism: A Randomized Controlled Trial	24
Efficacy and safety of low-dose acetylsalicylic acid for the prevention of thromboembolic events in individuals positive for antiphospholipid antibodies: A systematic review and meta-analysis	21
The Link Between Venous and Arterial Thrombosis: Is There a Role for Endothelial Dysfunction?	18
More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study	16
Totale	9.731

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	40.198
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	40.198

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	934	0	0	0	0	0	215	131	90	171	75	114	138
2021/2022	758	98	116	21	36	58	36	33	50	43	123	64	80
2022/2023	760	78	64	28	96	57	158	10	84	123	26	19	17
2023/2024	1.432	244	234	227	274	278	60	2	26	60	8	18	1
2024/2025	1.380	8	12	187	18	19	89	58	90	90	107	297	405
2025/2026	1.154	231	141	142	304	214	122	0	0	0	0	0	0
Totale													9.731